Study summary
Pirtobrutinib worked after earlier BTK inhibitors stopped working
82.5%response rate
What was tested
Pirtobrutinib, a non-covalent BTK inhibitor pill that still binds when the usual resistance mutation appears, for relapsed or refractory WM.
What they found
- Overall response rate was 82.5%.
- It was 81.0% in people who had already taken a covalent BTK inhibitor.
- Treatment was stopped for side effects in 15%.
What it means
Gives a next step after ibrutinib, zanubrutinib or acalabrutinib.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.